Stakeholder statement

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job
Labcorp and Thrive Global have launched a $159 direct-to-consumer test built around five cardiometabolic measures: apolipoprotein B, high-sensitivity C-reactive protein, HbA1c, blood pressure and BMI. Every measure has legitimate clinical relevance, but the bundle itself is not a validated cardiovascular risk score and it omits several assessments now central to guideline-based cardiovascular-kidney-metabolic care.

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

The protein boom has a cardiology blind spot

Not everyone needs a cardiologist. Everyone needs cardiovascular risk assessment

The Future of Cardiology Starts Before the First Heart Attack

From Patients to Customers: GLP-1 Marketing Is Rewriting Obesity Care

Britain Wants an AI-Enabled NHS. Scaling Innovation Is Still the Bottleneck

Breast Cancer Just Proved Why Biomarker Selection Matters

AI is moving inside the medical record. Privacy is only part of the risk

The mRNA Cancer Vaccine Story Just Got Less Comfortable
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
